Search results
Sep 7, 2022 · Among previously uninfected children, vaccine effectiveness reached 63.2% (95% confidence interval [CI], 61.0 to 65.2) at 4 weeks after the first dose and decreased to 15.5% (95% CI, 8.1 to 22.8...
Mar 27, 2023 · Whilst COVID-19 vaccination has been linked to an increased risk of myocarditis and other cardiac events in young people, we found no evidence of substantially increased mortality risk, either...
Oct 19, 2022 · In part 2, we randomly assigned young children (6 months to 5 years of age) in a 3:1 ratio to receive two 25-μg injections of mRNA-1273 or placebo, administered 28 days apart.
May 5, 2023 · In our observational paediatric study, we have characterised risk factors for long-term symptoms, using the WHO post COVID-19 condition definition, after delta infection and omicron reinfection. The study was designed to compare symptoms between children and adolescents.
Apr 18, 2023 · In children aged 5–11 years, mRNA vaccines are moderately effective against infections with the omicron variant, but are likely to protect well against COVID-19 hospitalisations. Vaccines were reactogenic but probably safe.
Nov 9, 2021 · During the phase 1 study, a total of 48 children 5 to 11 years of age received 10 μg, 20 μg, or 30 μg of the BNT162b2 vaccine (16 children at each dose level). On the basis of reactogenicity ...
Jun 14, 2022 · This test-negative, case-control analysis evaluates the association of symptomatic infection with prior vaccination with BNT162b2 to estimate vaccine effectiveness among children and adolescents during Omicron variant predominance.
